Literature DB >> 11456037

Haemochromatosis: iron still matters.

M L Bassett1.   

Abstract

Our ability to detect those predisposed to haemochromatosis is greatly enhanced by testing for HFE mutations. Ironically, this diagnostic advance has led to some confusion regarding the criteria for diagnosis of haemochromatosis, with overreliance on genetic testing instead of investigations for iron overload. Because many people who are homozygous for the C282Y mutation, or compound heterozygous for the C282Y and H63D mutations, either do not express or only partially express the disease, it is essential to confirm a diagnosis of haemochromatosis on the basis of increased body iron stores. Liver biopsy remains the best method of confirming this and has an important role in the patient with either borderline iron overload or advanced disease. Persistent elevation of serum ferritin concentration in the absence of overt liver damage, inflammation or neoplasia, and estimation of mobilized body iron by repeated phlebotomy, are reasonable alternatives to liver biopsy. Although the precise definition of iron overload is debated, a diagnosis of haemochromatosis cannot be made without demonstrating increased body iron stores.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11456037     DOI: 10.1046/j.1445-5994.2001.00050.x

Source DB:  PubMed          Journal:  Intern Med J        ISSN: 1444-0903            Impact factor:   2.048


  3 in total

Review 1.  Small bowel review: Normal physiology, part 1.

Authors:  Alan B R Thomson; Laurie Drozdowski; Claudiu Iordache; Ben K A Thomson; Severine Vermeire; M Tom Clandinin; Gary Wild
Journal:  Dig Dis Sci       Date:  2003-08       Impact factor: 3.199

2.  Mutations in the hereditary haemochromatosis gene HFE in professional endurance athletes.

Authors:  J L Chicharro; J Hoyos; F Gómez-Gallego; J G Villa; F Bandrés; P Celaya; F Jiménez; J M Alonso; A Córdova; A Lucia
Journal:  Br J Sports Med       Date:  2004-08       Impact factor: 13.800

3.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.